• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲磺酸伊马替尼可以通过作用于骨髓微环境来帮助将天然免疫导向抗白血病反应。

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.

机构信息

Unit of Molecular Oncology and Angiogenesis; San Martino Hospital-National Institute for Cancer Research; University of Genoa; Genoa, Italy.

出版信息

Oncoimmunology. 2012 Mar 1;1(2):214-216. doi: 10.4161/onci.1.2.18112.

DOI:10.4161/onci.1.2.18112
PMID:22720246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3377005/
Abstract

We discuss our recent findings on the increase, in chronic myeloid leukemia patients treated with imatinib, of B1 lymphocytes producing IgM anti-O-linked sugars expressed by leukemic cells, paralleled by increased B-stimulating cytokines. We propose that one important effect of imatinib treatment is due to the remodelling of bone marrow microenvironment.

摘要

我们讨论了我们最近在慢性髓性白血病患者中发现的现象，即在接受伊马替尼治疗的患者中，产生 IgM 抗-O 连接糖的 B1 淋巴细胞增加，同时伴有 B 细胞刺激细胞因子增加。我们提出，伊马替尼治疗的一个重要作用是由于骨髓微环境的重塑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf44/3377005/1f651e7a7b16/onci-1-214-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf44/3377005/1f651e7a7b16/onci-1-214-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf44/3377005/1f651e7a7b16/onci-1-214-g1.jpg

相似文献

1
Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.甲磺酸伊马替尼可以通过作用于骨髓微环境来帮助将天然免疫导向抗白血病反应。
Oncoimmunology. 2012 Mar 1;1(2):214-216. doi: 10.4161/onci.1.2.18112.
2
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.伊马替尼治疗诱导慢性髓系白血病患者产生 CD5+B 淋巴细胞和具有抗白血病反应性的 IgM 天然抗体。
PLoS One. 2011 Apr 18;6(4):e18925. doi: 10.1371/journal.pone.0018925.
3
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.复发/难治性急性髓系白血病患者接受克拉屈滨、阿糖胞苷（Ara-C）、粒细胞集落刺激因子（G-CSF）（CLAG方案）及同步递增剂量甲磺酸伊马替尼（格列卫）的I期研究。
Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.
4
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.骨髓间充质基质细胞通过 CXCR4/CXCL12 轴非选择性地保护慢性髓性白血病细胞免受伊马替尼诱导的凋亡。
Haematologica. 2010 Jul;95(7):1081-9. doi: 10.3324/haematol.2009.017178. Epub 2010 Feb 23.
5
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.慢性髓性白血病的治疗选择：伊马替尼对比干扰素对比异基因移植。
Curr Opin Oncol. 2004 Mar;16(2):95-9. doi: 10.1097/00001622-200403000-00002.
6
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.K562/GM-CSF 免疫疗法可降低伊马替尼治疗后仍有疾病残留的慢性髓性白血病患者的肿瘤负担。
Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.
7
[Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].甲磺酸伊马替尼对慢性髓性白血病患者骨髓单个核细胞来源树突状细胞发育的影响
Zhonghua Yi Xue Za Zhi. 2006 Aug 29;86(32):2252-5.
8
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.慢性髓系白血病干细胞的清除：一种新的数学模型预测，在伊马替尼基础上加用粒细胞集落刺激因子无治疗益处。
PLoS Comput Biol. 2009 Sep;5(9):e1000503. doi: 10.1371/journal.pcbi.1000503. Epub 2009 Sep 11.
9
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.对接受甲磺酸伊马替尼治疗的慢性粒细胞白血病（CML）患者的BCR-ABL转录本进行连续监测。
Med Oncol. 2004;21(4):349-58. doi: 10.1385/MO:21:4:349.
10
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.对于因Bcr/Abl诱导的白血病而接受甲磺酸伊马替尼治疗的小鼠，中枢神经系统是白血病细胞的一个庇护所。
Blood. 2003 Jun 15;101(12):5010-3. doi: 10.1182/blood-2002-10-3059. Epub 2003 Feb 20.

引用本文的文献

1
Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).袋獾（袋獾属哈里斯袋獾）的免疫球蛋白动态与癌症患病率
Sci Rep. 2016 Apr 29;6:25093. doi: 10.1038/srep25093.
2
Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy.甲磺酸伊马替尼治疗的慢性髓性白血病患者不同反应组及分期中白细胞介素1β血清水平的评估
Indian J Hematol Blood Transfus. 2014 Dec;30(4):247-52. doi: 10.1007/s12288-014-0339-7. Epub 2014 Feb 7.
3
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.

本文引用的文献

1
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.伊马替尼治疗诱导慢性髓系白血病患者产生 CD5+B 淋巴细胞和具有抗白血病反应性的 IgM 天然抗体。
PLoS One. 2011 Apr 18;6(4):e18925. doi: 10.1371/journal.pone.0018925.
2
Effects of imatinib mesylate in osteoblastogenesis.甲磺酸伊马替尼对成骨细胞生成的影响。
Exp Hematol. 2009 Apr;37(4):461-8. doi: 10.1016/j.exphem.2008.12.008.
3
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
达沙替尼在表达颗粒酶B的T细胞中促进Th1型反应。
Oncoimmunology. 2014 May 29;3:e28925. doi: 10.4161/onci.28925. eCollection 2014.
4
Current trends of anticancer immunochemotherapy.抗癌免疫化学疗法的当前趋势。
Oncoimmunology. 2013 Jun 1;2(6):e25396. doi: 10.4161/onci.25396. Epub 2013 Jun 13.
接受伊马替尼一线治疗慢性髓性白血病患者的六年随访
Leukemia. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12.
4
Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?针对人类肿瘤的细胞毒性天然抗体：抗癌免疫疗法的一种选择？
Autoimmun Rev. 2008 Jun;7(6):491-5. doi: 10.1016/j.autrev.2008.03.012. Epub 2008 Apr 10.
5
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.第一部分：慢性髓性白血病对伊马替尼耐药的机制
Lancet Oncol. 2007 Nov;8(11):1018-29. doi: 10.1016/S1470-2045(07)70342-X.
6
VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF.来自人骨髓的血管细胞黏附分子-1阳性基质细胞可产生针对B系祖细胞和浆细胞的细胞因子：基质细胞衍生因子-1、fms样酪氨酸激酶3配体和B细胞激活因子。
Mol Immunol. 2007 Mar;44(7):1606-12. doi: 10.1016/j.molimm.2006.08.021. Epub 2006 Oct 25.
7
Imatinib mesylate--uncovering a fast track to adaptive immunity.
N Engl J Med. 2006 May 25;354(21):2282-4. doi: 10.1056/NEJMcibr061878.
8
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.甲磺酸伊马替尼（STI571）通过逆转异常增加的增殖来抑制慢性粒细胞白血病中原始恶性祖细胞的生长。
Blood. 2002 May 15;99(10):3792-800. doi: 10.1182/blood.v99.10.3792.
9
B1 cells: similarities and differences with other B cell subsets.B1细胞：与其他B细胞亚群的异同
Curr Opin Immunol. 2001 Apr;13(2):195-201. doi: 10.1016/s0952-7915(00)00204-1.
10
Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells.基质衍生因子-1α对正常和慢性粒细胞白血病CD34+造血细胞的生物学效应。
Leukemia. 2000 Sep;14(9):1652-60. doi: 10.1038/sj.leu.2401875.